Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview

Reuters03-23

* Kinnate Biopharma Inc is expected to show no change in quarterly revenue when it reports results on March 25 (estimated) for the period ending December 31 2023

*

* LSEG's mean analyst estimate for Kinnate Biopharma Inc is for a loss of 44 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months.

* Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50, below its last closing price of $2.65.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Sep. 30 2023 -0.67 -0.67 -0.65 Beat 3.7

Jun. 30 2023 -0.78 -0.75 -0.68 Beat 9.3

Mar. 31 2023 -0.70 -0.73 -0.73 Met 0

Dec. 31 2022 -0.72 -0.72 Met -0.6

Sep. -0.60 -0.61 -0.70 Missed -15.2

30 2022

Jun. 30 2022 -0.66 -0.64 -0.62 Beat 2.9

Mar. 31 2022 -0.62 -0.61 -0.61 Met -0.5

Dec. 31 2021 -0.60 -0.59 -0.60 Missed -2.2

This summary was machine generated March 22 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2421878665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-23 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2421878665","market":"us","top_or_hot":-1,"title":"Kinnate Biopharma Inc    expected to post a loss of 44 cents a share - Earnings Preview","media":"Reuters","content":"<html><body><p>* Kinnate Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on March 25 (estimated) for the period ending December 31 2023</p><p>   * </p><p>   * LSEG's mean analyst estimate for Kinnate Biopharma Inc is for a loss of 44 cents per share. </p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\"  </p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50, below its last closing price of $2.65. </p><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><p>QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI</p><p>ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %</p><p>              E®                               MISSED  </p><p>Sep. 30 2023  -0.67       -0.67      -0.65     Beat    3.7</p><p>Jun. 30 2023  -0.78       -0.75      -0.68     Beat    9.3</p><p>Mar. 31 2023  -0.70       -0.73      -0.73     Met     0</p><p>Dec. 31 2022              -0.72      -0.72     Met     -0.6</p><p>Sep.        -0.60       -0.61      -0.70     Missed  -15.2</p><p>30 2022                                                </p><p>Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.9</p><p>Mar. 31 2022  -0.62       -0.61      -0.61     Met     -0.5</p><p>Dec. 31 2021  -0.60       -0.59      -0.60     Missed  -2.2</p><p>This summary was machine generated March 22 at 21:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kinnate Biopharma Inc    expected to post a loss of 44 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKinnate Biopharma Inc    expected to post a loss of 44 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-23 05:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Kinnate Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on March 25 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNTE","symbol_name":"Kinnate BioPharma Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2421878665","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2421878665","pubTimestamp":1711141450,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Kinnate Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on March 25 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst esti","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KNTE":"Kinnate BioPharma Inc."},"translate_title":"Kinnate Biopharma Inc。预计每股亏损44美分——收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNTE":1},"content_text":"* Kinnate Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on March 25 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst estimate for Kinnate Biopharma Inc is for a loss of 44 cents per share.    * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" 3 \"hold\" and no \"sell\" or \"strong sell.\"     * The mean earnings estimate of analysts was unchanged in the last three months.    * Wall Street's median 12-month price target for Kinnate Biopharma Inc is $2.50, below its last closing price of $2.65. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRIENDING        ARTESTIMAT  ESTIMATE             MET,    SE %              E®                               MISSED  Sep. 30 2023  -0.67       -0.67      -0.65     Beat    3.7Jun. 30 2023  -0.78       -0.75      -0.68     Beat    9.3Mar. 31 2023  -0.70       -0.73      -0.73     Met     0Dec. 31 2022              -0.72      -0.72     Met     -0.6Sep.        -0.60       -0.61      -0.70     Missed  -15.230 2022                                                Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.9Mar. 31 2022  -0.62       -0.61      -0.61     Met     -0.5Dec. 31 2021  -0.60       -0.59      -0.60     Missed  -2.2This summary was machine generated March 22 at 21:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2421878665"}